Glioblastoma are the most common and aggressive primary brain tumors in adults. Despite optimal treatment with surgery, radiotherapy, and temozolomide chemotherapy, patients with malignant gliomas are still at high risk of tumor recurrences and have poor prognoses. Malignant gliomas are often highly vascularized. But in the last few decades, significant advances have been made in the study of the mechanisms of tumor angiogenesis. Bevacizumab, an antibody against vascular endothelial growth factor, has demonstrated significant activity in recurrent glioblastomas. Thus in this article, we reviewed the principles and research progress of bevacizumab in the treatment of malignant gliomas, hoping to provide a strong scientific basis for the clinical application of bevacizumab.